# Meningococcal Vaccines—High-risk Populations

## Risk groups:
- **7–23 months**
- **9–23 months**
- **2 years and older**

## Age at first dose | Exp | CD | Asp | HIV | Booster for those who remain at increased risk
---|---|---|---|---|---
2–6 months | ✓ | ✓ | ✓ | ✓ | If primary dose(s) given when younger than 7 years:
| 2 months | ACWY-CRM Menveo® | 4 months | ACWY-CRM Menveo® | 6 months | ACWY-CRM Menveo® | 12–15 months | ACWY-CRM Menveo® |
7–23 months | ✓ | ✓ | ✓ | | If primary dose(s) given at age 7 years or older:
| 3 months | ACWY-CRM Menveo® | | ACWY-CRM Menveo® | | Every 5 years | Menveo® or Menactra® |
9–23 months | ✓ | ✓ | | | Every 5 years | Menveo® or Menactra® |
2 years and older | ✓ | ✓ | ✓ | ✓ | Every 5 years | Menveo® or Menactra® |

## For further details, see [www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html). For routine use, see EZIZ.org/assets/docs/IMM-1217.pdf.

1. Information on outbreaks at [https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/meningococcal.aspx](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/meningococcal.aspx)
2. Abbreviations: ACWY/ACWY-CRM/ACWY-D = MenACWY = MCV4
3. Minimum age 12 months.
4. MenACWY-D (Menactra®) is licensed starting at 9 months.
5. If MenACWY-D (Menactra®) is used for persons with asplenia or HIV infection, defer until age 2 years and at least 4 weeks after completion of PCV13 series.
6. It is recommended that MenACWY-D be given either before, or concomitantly with, the next recommended dose of DTaP vaccine.
7. If no longer at high risk by age 10, administer additional two doses of MenACWY according to the regular adolescent schedule at age 11–12 years and age 16 years.

This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC)